CD22 and congenital rubella syndrome: Some of the unexpected distinctions reported by Shah and colleagues included 5% incidence of atypical hemolytic uremic syndrome, 5% incidence of severe capillary leak syndrome out of proportion to CRS, and 21% incidence of ocular symptoms following CD22-directed CAR-T therapy.